Mechanism of action
Despite the fact that stroke is one of the most common causes of death worldwide and the leading cause of neurological disability, there is a shortage of drugs directly targeting the secondary damage that occurs in the brain in the hours and days following the acute onset of illness. The Edvince approach is unique and fundamentally different from all previous and unsuccessful attempts to treat stroke patients. It represents a paradigm shift in how we can improve therapy in stroke with the potential to revolutionize the outcome.
Cerebrovascular Changes in Stroke – biochemical processes start that cause oxygen deficiency
Edvince’s initial drug candidate, EDV2209, is a small molecule that selectively inhibits MEK1/2 – a key enzyme in the intracellular MEK/ERK1/2 signalling pathway in the smooth muscle cells in the walls of the brain’s blood vessels, which is activated in connection with an ischemic stroke or cerebral haemorrhage. This signalling leads to the upregulation of ‘contractile receptors’ in the brain’s blood vessels, causing a series of increased vascular contractions that occur over time, and reduced blood flow resulting in oxygen deprivation and ultimately cell death – ischemia
Time course of cerebral vasospasm
By blocking this cascade at an early stage, EDV2209 aims to prevent the delayed brain damage that often occurs days after the initial onset of the illness – an area where current treatments are not sufficiently effective.
Upregulation of contractile receptors in smooth muscle cells in arteries after stroke
Upregulation of contractile receptors in smooth muscle cells in arteries after stroke
Contact
Medicon Village
223 81 Lund. Sweden
info@edvince.com